AOTI, Inc. AOTI

Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0) nearly doubled revenues to CHF 77.2 million in 2025, driven by strong AGAMREE sales across Europe.  The company expects to hit cash flow breakeven in Q3 2026 without raising additional capital. AOTI Inc (AIM:AOTI) has published a major study showing its wound oxygen therapy healed 64.8% of patients with chronic wounds that had resisted treatment for an average of seven months.  The study, which involved 3,126-patients, also reported hospitalisation rates of just 3.7% and amputation rates of 6.1%. Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF,

Oscillate PLC (LSE:SRVL), which is rebranding as Serval Resources, has begun trading on AIM after completing its acquisition of Kalahari Copper. The company raised nearly £3 million to fund copper exploration across Namibia, Botswana and Côte d'Ivoire. Bango PLC (AIM:BGO, OTCQX:BGOPF) has set a target for its subscriptions division to reach positive cash earnings in 2027, after Q1 revenue rose 13% and adjusted EBITDA jumped 39%. Active subscriptions on its Digital Vending Machine platform are up nearly 60% year-on-year to 24 million. AOTI Inc (AIM:AOTI) has published a large real-world study